Despite good data, Ironwood’s shares plummet 

Off Biotech, biotechnology, Business, drug development, drug prices, drug pricing, finance, global health, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, Politics, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we’ll discuss how the U.S. government is cracking down on Chinese biotechs, and how that might affect the industry stateside. Also, a positive clinical trial for Ironwood Pharmaceuticals still causes a stock slump, and more.

Read the rest…

Read Original Article: Despite good data, Ironwood’s shares plummet  »

About The Author